Short and Medium Term Therapies for the Treatment of COVID-19: Senolytics and Vaccine Development

According to the WHO, hypertension, cardiovascular and chronic respiratory diseases, diabetes, immunosuppression, cancer, along with old age, belong to the specific risk group of people affected by the current COVID-19 pandemic. As we age, our body accumulates senescent cells, which produce harmful effects in the body, and are known to play a causal role in the appearance of the diseases indicated above. This fact, together with data that is becoming known, place senescent cells as targets to eliminate or alleviate the symptoms of infection. The main objective of this project is the specific elimination of senescent cells through the use of senolytics, in order to improve the clinical picture of those affected. The fact that some senolytics are already in the clinical phase, means that its use in patients would be faster. The development of vaccines based on cellular response is also raised here.